

Registration

Online registration available through CASL homepage (www.hepatology.ca)

REGISTRATION FEES (CAD \$):

Prior to June 30, 2017	
CASL members	\$200
Non-members	\$400
Trainees	\$100
From July 1, 2017	
CASL members	\$250
Non-members	\$450
Trainees	\$150
On-site	
CASL members	\$300
Non-members	\$500
Trainees	\$200

Venue & Accommodation

Hotel Fort Garry

222 Broadway
Winnipeg, Manitoba R3C 0R3, Canada
Phone: (204) 942-8251

To secure meeting rates (CAD \$159 + taxes per Queen, King or Double/Double room for single or double occupancy), book prior to August 8, 2017 by calling (204) 942-8251 or Toll Free 1-800-665-8088 and use meeting code (10V962). The number of reserved rooms is limited and will be sold on first come/first served basis.

For information on the meeting, accreditation and registration, please contact:

Karen Kiel or Ingrid Reuter

Health Sciences Centre
GC430-820 Sherbrook Street
Winnipeg MB R3A 1R9

Phone: 204-787-7770

Fax: 204-787-3159

E-mail: KKiel@exchange.hsc.mb.ca or IReuter@exchange.hsc.mb.ca



The Canadian Association for the Study of the Liver (CASL) is a non-profit organization whose members represent a multidisciplinary group of scientists and healthcare professionals who provide national leadership in all aspects of liver research, education and patient care. Website: www.hepatology.ca



Canadian Liver Foundation
Fondation canadienne du foie

The Canadian Liver Foundation (CLF) is "bringing liver research to life" by promoting liver health, improving public awareness and understanding of liver disease, raising funds for research and providing support to individuals affected by liver disease. Website: www.liver.ca

The Canadian Liver Foundation acknowledges the following organizations for their support of the CLF's mission of "bringing liver research to life" to benefit the liver health of all Canadians through research, education, patient support and advocacy.

Unrestricted educational grants* provided by



Astellas Pharma Canada Inc
Alexion Pharma Canada
Canadian Institutes of Health Research -
Institute of Nutrition, Metabolism & Diabetes
GMD Pharma Solutions
KNS Canada


Additional support provided by

Department of Medicine, University of Manitoba

In keeping with the Canadian Medical Association Guidelines, program content and selection of speakers are the sole responsibility of the Scientific Committee. Funders have had no input into the content, speakers or activities of this meeting.

* Confirmed as at time of printing (2017-06-07)

2017 International Meeting on Non-Alcoholic Fatty Liver Disease (NAFLD)



September 9 – 11, 2017

Hotel Fort Garry
Winnipeg, Manitoba
Canada

Presented By:



Co-Sponsored By:



Canadian Liver Foundation
Fondation canadienne du foie



Purpose of the meeting

In parallel with the obesity/diabetes epidemic, the incidence and prevalence of NAFLD continues to rise in Canada and elsewhere. While NAFLD leads to an increasing health care burden, our understanding and the therapeutic options remain limited. It is therefore imperative that the level of knowledge and understanding of this liver disease be increased. This will require a multi-pronged approach to adequately address it from prevention, diagnosis, management, treatment and research perspectives.

The purpose of the meeting includes:

- Reviewing current knowledge on NAFLD from various perspectives
- Determining knowledge gaps to be filled by future research
- Fostering informal exchange between leaders in the field and engage young investigators
- Fostering research collaboration on NAFLD within Canada, North America and beyond

Participants

The 1.5-day education program aims to attract an estimated audience of 100 attendees with the target audience being

- Clinicians (of any background) interested in NAFLD
- Young investigators with an academic interest in NAFLD
- Scientists interested in NAFLD

Scientific Co-Chairs

Eberhard L. Renner
Past President CASL
Professor and Head,
Department of Internal
Medicine, Max Rady
College of Medicine,
University of Manitoba
Winnipeg, MB, Canada

Brent A. Neuschwander-Tetri
Professor of Internal Medicine
Director, Division of
Gastroenterology and
Hepatology and Director
NASH Studies Unit, Saint Louis
University School of Medicine,
St. Louis, MO, USA

Saturday, September 9, 2017		
1900	Welcome Reception & Registration	
Sunday, September 10, 2017		
0700	Breakfast & Registration	
Session I – Clinical		
0800	Magnitude of the problem - epidemiologic overview	Jeanne-Marie Giard, CHUM, Montreal, QC
0830	Natural history, clinical/factors associated with progression of disease	Gerald Minuk, UM, Winnipeg
0900	Histopathological features and grading/staging	David Kleiner, NIH, Bethesda, MD
Coffee Break		
1000	Non-invasive diagnostic tests (CAP Fibroscan, imaging, serological tests)	Keyur Patel, UHN, Toronto, ON
1030	The pediatric perspective	Eve Roberts, Dalhousie, Halifax, NS
1100	Break-out sessions and report back	
	• Which are the epidemiological and clinical knowledge gaps – which are the high priority areas for further study?	
	• How should we diagnose NASH in clinical practice – which are the most promising non-invasive approaches to be further developed/evaluated?	
	• Which are the most relevant endpoints for future interventional clinical trials?	
Lunch		
Session II - Pathogenetic Factors		
1400	Pathomechanisms leading to NAFLD – overview	Brent Neuschwander-Tetri, SLU, St Louis, MO
1430	Genetic polymorphisms predisposing to NASH	Anne Daly, Newcastle University, Newcastle, UK
1500	NAFLD and nutrition – is it just about calories?	Saumya Jayakumar, University of Calgary, AB
Coffee Break		
1600	NAFLD and the gut microbiome	Marialena Mouzaki, SickKids, Toronto, ON
1630	Cellular Senescence: missing link between HCC and fatty liver disease?	Aloysious D. Aravinthan, Nottingham, UK
1700	Break-out sessions and report back	
	• Which are the pathomechanistic knowledge gaps – which are the high priority areas for further studies?	
	• Which mechanism(s) are potentially involved in governing transition from steatosis to steatohepatitis and merit further study?	
	• Which pathomechanisms might serve as potential therapeutic targets?	
Dinner		
Monday, September 11, 2017		
0730	Breakfast	
Session III – Therapy		
0800	Life Style measures	Kathleen Corey, Harvard/MGH, Boston, MA
0830	Current and emerging pharmacotherapeutic options	Brent Neuschwander-Tetri, SLU, St. Louis, MO
0900	The role of bariatric surgery	Stavra Xanthakos, Children's Hospital, Cincinnati, OH
0930	Liver Transplantation	Kymerly Watt, Mayo Clinic, Rochester, MN
Coffee Break		
1030	Break-out sessions and report back	
	• Which are the knowledge gaps with currently available therapeutic options – which are the high priority areas for further study?	
	• How are life style measures best administered in clinical practice (setting)?	
	• Who will/should treat NAFLD today and in the future?	
1200	Adjourn - Boxed Lunch	

Program subject to change without notice. Please visit www.liver.ca/2017NAFLDMeeting or www.hepatology.ca for updated information

"This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and approved by Canadian Association for the Study of the Liver."